Prime Medicine Cuts Jobs, Names New CEO in Strategic Pivot

Dow Jones
05-19

By Dean Seal

 

Prime Medicine is cutting 25% of its workforce and bringing in a new chief executive as it pivots to focus on its liver franchise and programs that aren't internally funded.

The biotechnology company said Monday that it is deprioritizing its chronic granulomatous disease programs as part of a major overhaul that should cut its operating costs and cash burn almost in half through 2027.

In tandem with the restructuring, Keith Gottesdiener is departing as chief executive and a member of Prime's board.

Allan Reine, the company's chief financial officer, has been named CEO and will become a member of the board. Jeff Marrazzo, another director, has been named executive chair.

Prime's shares fell 8.2% to $1.46 in premarket trading.

 

Write to Dean Seal at dean.seal@wsj.com

 

(END) Dow Jones Newswires

May 19, 2025 09:24 ET (13:24 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10